P_global values for the androgen-to-estrogen sub-pathway for all cases and for PMS ER+ cases in the Swedish sample set, adjusted for reproductive and hormone risk factors.

*: HRT use, the AML Pglobal values were adjusted by a categorical variable, HRT/nonHRT. Similarly, Parity, adjusted by none/one or more children; Age at first time birth, adjusted by <25yrs, 25–30yrs, 30–35yrs and > = 35yrs; Age at menarche, adjusted by > = 14yrs, 12–13yrs and < = 12yrs; Age at menopause, adjusted by <45yrs, 45–50yrs, 50–55yrs and > = 55yrs. All AML Pglobal values are based on 5,000 permutations. PMS: postmenopausal and sporadic.*：激素替代疗法（Hormone Replacement Therapy, HRT）使用情况：AML全局P值按分类变量HRT/非HRT进行校正。同理，孕产次按无子女、1名及以上子女分组进行校正；首次生育年龄按<25岁、25~30岁、30~35岁及≥35岁分组进行校正；月经初潮年龄按≥14岁、12~13岁及≤12岁分组进行校正；绝经年龄按<45岁、45~50岁、50~55岁及≥55岁分组进行校正。所有AML全局P值均基于5000次置换检验。PMS：绝经后散发性（postmenopausal and sporadic）。